Human vδ2 versus non-vδ2 γδ t cells in antitumor immunity

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Kabelitz, Dieter ^a   Kalyan, Shirin ^a   Oberg, Hans Heinrich ^a   Wesch, Daniela ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

T cells; Cancer immunosurveillance; Cytotoxicity; V 1 T cells; V 2 T cells

Indexed keywords

AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CROSS LINKING; CROSS PRESENTATION; CYTOKINE PRODUCTION; DRUG EFFICACY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LOW DRUG DOSE; MOLECULAR DYNAMICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASTICITY; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; V DELTA 2 GAMMA DELTA T LYMPHOCYTE;

EID: 84886944509     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23304     Document Type: Article

References (59)

1. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31:184-96; PMID:19699170; http://dx.doi.org/10.1016/j.immuni.2009.08.006.
2. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10:467-78; PMID:20539306; http://dx.doi.org/10.1038/nri2781.
3. Morita CT, Mariuzza RA, Brenner MB. Antigen recognition by human γ δ T cells: pattern recognition by the adaptive immune system. Springer Semin Immunopathol 2000; 22:191-217; PMID:11116953; http://dx.doi.org/10.1007/s002810000042.
4. Pang DJ, Neves JF, Sumaria N, Pennington DJ. Understanding the complexity of γδ T-cell subsets in mouse and human. Immunology 2012; 136:283-90; PMID:22385416; http://dx.doi.org/10.1111/j.1365-2567.2012.03582.x.
5. Kabelitz D, He W. The multifunctionality of human Vγ9V δ2 γδ T cells: clonal plasticity or distinct subsets? Scand J Immunol 2012; 76:213-22; PMID:22670577; http://dx.doi.org/10.1111/j.1365-3083.2012.02727.x.
6. Meuter S, Eberl M, Moser B. Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci U S A 2010; 107:8730-5; PMID:20413723; http://dx.doi.org/10.1073/pnas.1002769107.
7. Braza MS, Klein B. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Br J Haematol 2013; 160:123-32; PMID:23061882; http://dx.doi.org/10.1111/bjh.12090.
8. Siegers GM. Anti-leukemia activity of human γ δ T cells. Oncoimmunology 2012; 1:237-9; PMID:22720255; http://dx.doi.org/10.4161/onci.1.2.18231.
9. Hannani D, Ma Y, Yamazaki T, Déchanet-Merville J, Kroemer G, Zitvogel L. Harnessing γδ T cells in anticancer immunotherapy. Trends Immunol 2012; 33:199-206; PMID:22364810; http://dx.doi.org/10.1016/j.it.2012.01.006.
10. Kalyan S, Kabelitz D. Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol 2013; 10:21-9; PMID:23085947; http://dx.doi.org/10.1038/cmi.2012.44.
11. Holtmeier W, Pfänder M, Hennemann A, Zollner TM, Kaufmann R, Caspary WF. The TCR-d repertoire in normal human skin is restricted and distinct from the TCR-d repertoire in the peripheral blood. J Invest Dermatol 2001; 116:275-80; PMID:11180004; http://dx.doi.org/10.1046/j.1523-1747.2001.01250.x.
12. Wang H, Fang Z, Morita CT. Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J Immunol 2010; 184:6209-22; PMID:20483784; http://dx.doi.org/10.4049/jimmunol.1000231.
13. Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, Kollas AK, et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett 2001; 509:317-22; PMID:11741609; http://dx.doi.org/10.1016/S0014-5793(01)03191-X.
14. Puan KJ, Jin C, Wang H, Sarikonda G, Raker AM, Lee HK, et al. Preferential recognition of a microbial metabolite by human Vgamma2Vdelta2 T cells. Int Immunol 2007; 19:657-73; PMID:17446209; http://dx.doi.org/10.1093/intimm/dxm031.
15. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human γ δ T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 2007; 66:320-8; PMID:17635809; http://dx.doi.org/10.1111/j.1365-3083.2007.01963.x.
16. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182:7287-96; PMID:19454726; http://dx.doi.org/10.4049/jimmunol.0804288.
17. Gomes AQ, Correia DV, Grosso AR, Lança T, Ferreira C, Lacerda JF, et al. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells. Haematologica 2010; 95:1397-404; PMID:20220060; http://dx.doi.org/10.3324/haematol.2009.020602.
18. Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, et al. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012; 188:4701-8; PMID:22467661; http://dx.doi.org/10.4049/jimmunol.1103710.
19. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-8; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500.
20. Benzaïd I, Mönkkönen H, Stresing V, Bonnelye E, Green J, Mönkkönen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011; 71:4562-72; PMID:21646473; http://dx.doi.org/10.1158/0008-5472.CAN-10-3862.
21. Dai Y, Chen H, Mo C, Cui L, He W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/ virus immunity. J Biol Chem 2012; 287:16812-9; PMID:22433851; http://dx.doi.org/10.1074/jbc.M111.327650.
22. Mo C, Dai Y, Kang N, Cui L, He W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin- 18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J Biol Chem 2012; 287:19242-54; PMID:22493490; http://dx.doi.org/10.1074/jbc.M112.349936.
23. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ 9Vδ 2 T cells by NKG2D. J Immunol 2005; 175:2144-51; PMID:16081780.
24. Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/ lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood 2010; 115:2407-11; PMID:20101024; http://dx.doi.org/10.1182/blood-2009-08-237123.
25. Shojaei H, Oberg HH, Juricke M, Marischen L, Kunz M, Mundhenke C, et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 2009; 69:8710-7; PMID:19887600; http://dx.doi.org/10.1158/0008-5472.CAN-09-1602.
26. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, et al. Vγ 9 Vδ 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int J Cancer 2008; 122:2526-34; PMID:18307255; http://dx.doi.org/10.1002/ijc.23365.
27. Capietto AH, Martinet L, Fournié JJ. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol 2011; 187:1031-8; PMID:21670311; http://dx.doi.org/10.4049/jimmunol.1100681.
28. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545.
29. Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human Vγ 9Vδ 2 γ δ T cells in vitro and in SCID mice in vivo. J Immunol 2004; 173:6767-76; PMID:15557170.
30. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. Vγ 9Vδ 2 T lymphocytes efficiently recognize and kill zoledronatesensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010; 184:3260-8; PMID:20154204; http://dx.doi.org/10.4049/jimmunol.0903454.
31. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67:7450-7; PMID:17671215; http://dx.doi.org/10.1158/0008-5472.CAN-07-0199.
32. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011; 60:1447-60; PMID:21647691; http://dx.doi.org/10.1007/s00262-011-1049-8.
33. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, et al. Tumorpromoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother 2012; 35:205-13; PMID:22306909; http://dx.doi.org/10.1097/CJI.0b013e318245bb1e.
34. Kalyan S, Quabius ES, Wiltfang J, Mönig H, Kabelitz D. Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug-effects of aminobisphosphonate therapy. J Bone Miner Res 2012; In Press; PMID:22991330; http://dx.doi.org/10.1002/jbmr.1769.
35. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293.
36. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011; 60:1075-84; PMID:21519826; http://dx.doi.org/10.1007/s00262-011-1021-7.
37. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, et al. Questionable relevance of γ δ T lymphocytes in renal cell carcinoma. J Immunol 2008; 180:3578-84; PMID:18292585.
38. Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55:1072-80; PMID:16328383; http://dx.doi.org/10.1007/s00262-005-0094-6.
39. Siegers GM, Dhamko H, Wang XH, Mathieson AM, Kosaka Y, Felizardo TC, et al. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy 2011; 13:753-64; PMID:21314241; http://dx.doi.org/10.3109/14653249.2011.553595.
40. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011; 118:992-1001; PMID:21633088; http://dx.doi.org/10.1182/blood-2011-02-339135.
41. Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy 2012; 14:1110-8; PMID:22800570; http://dx.doi.org/10.3109/14653249.2012.700766.
42. Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti JL, Gobbi M, et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood 2007; 109:2078-85; PMID:16973957; http://dx.doi.org/10.1182/blood-2006-06-028985.
43. Xu B, Pizarro JC, Holmes MA, McBeth C, Groh V, Spies T, et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci U S A 2011; 108:2414-9; PMID:21262824; http://dx.doi.org/10.1073/pnas.1015433108.
44. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019.
45. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64:9172-9; PMID:15604289; http://dx.doi.org/10.1158/0008-5472.CAN-04-2417.
46. Siegers GM, Ribot EJ, Keating A, Foster PJ. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother 2012; In Press; PMID:23100099; http://dx.doi.org/10.1007/s00262-012-1353-y.
47. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Cancer Lett 2010; 297:126-36; PMID:20537791; http://dx.doi.org/10.1016/j.canlet.2010.05.005.
48. Déchanet J, Merville P, Lim A, Retière C, Pitard V, Lafarge X, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103:1437-49; PMID:10330426; http://dx.doi.org/10.1172/JCI5409.
49. Halary F, Pitard V, Dlubek D, Krzysiek R, de la Salle H, Merville P, et al. Shared reactivity of Vδ2(neg) γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med 2005; 201:1567-78; PMID:15897274; http://dx.doi.org/10.1084/jem.20041851.
50. Devaud C, Bilhere E, Loizon S, Pitard V, Behr C, Moreau JF, et al. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Cancer Res 2009; 69:3971-8; PMID:19383918; http://dx.doi.org/10.1158/0008-5472.CAN-08-3037.
51. Couzi L, Levaillant Y, Jamai A, Pitard V, Lassalle R, Martin K, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010; 21:181-8; PMID:19713314; http://dx.doi.org/10.1681/ASN.2008101072.
52. Willcox CR, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T, et al. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13:872-9; PMID:22885985; http://dx.doi.org/10.1038/ni.2394.
53. Moser B, Eberl M. γδ T-APCs: a novel tool for immunotherapy? Cell Mol Life Sci 2011; 68:2443-52; PMID:21573785; http://dx.doi.org/10.1007/s00018-011-0706-6.
54. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 2012; 188:1708-16; PMID:22250090; http://dx.doi.org/10.4049/jimmunol.1102654.
55. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing γ δ T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269.
56. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27:334-48; PMID:17656116; http://dx.doi.org/10.1016/j.immuni.2007.05.020.
57. Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. Cutting edge: TGF-β1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation. J Immunol 2009; 183:3574-7; PMID:19710458; http://dx.doi.org/10.4049/jimmunol.0901334.
58. Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139:206-16; PMID:17897296; http://dx.doi.org/10.1111/j.1365-2141.2007.06754.x.
59. Li Y, Wang Q, Mariuzza RA. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med 2011; 208:703-14; PMID:21422170; http://dx.doi.org/10.1084/jem.20102548.